Rapt Therapeutics Inc.

RAPT Therapeutics, a clinical‑stage immunology biopharma, develops oral small‑molecule CCR4 antagonists—lead oncology asset FLX475 (Phase 1/2) and inflammation asset RPT193—for advanced cancer and unmet inflammatory needs.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 60
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
RAPT	Rapt Therapeutics Inc. Cap: 0.9B	EQUITY	NMS	USD	US75382E1091	Active	📈